BLFS

Business Context and Reporting Period

Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: The Company develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions (HypoThermosol and CryoStor) for cells, tissues, and organs. It also provides contracted R&D and consulting services. The Company is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 10% year-over-year (YoY) for the six-month period, driven by a 12% increase in product sales due to new customer acquisition. However, licensing revenue declined 37%.
• Expense Increases: Operating expenses rose 34% YoY. Significant drivers included:
  • Manufacturing Start-up Costs: $385,205 incurred in 2009 (none in 2008) as the Company transitioned manufacturing in-house.
  • Sales and Marketing: Increased 94% YoY due to new hires, trade show expenses, and advertising.
  • Research and Development: Increased 28% YoY due to personnel costs and lab facility build-out.
• Cost of Sales: Increased 16% YoY, primarily due to higher costs from the contract manufacturing organization (CMO) prior to the in-house transition. Gross margin percentage decreased from 35% to 31%.
• Debt Position: Principal balance on related-party promissory notes increased by approximately $1.9 million during the period to $6.96 million. Interest expense increased 81% YoY.
• Liquidity: Cash balance decreased slightly to $86,403. The Company utilized $1.9 million in financing proceeds to offset operating cash burn.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management states that the accumulated deficit of approximately $49 million and inability to generate sufficient income from operations raise substantial doubt about the Company's ability to continue as a going concern.
• Liquidity Strategy: The Company relies heavily on the "Secured Convertible Multi-Draw Term Loan Facilities" provided by related parties (Thomas Girschweiler and Walter Villiger). As of June 30, 2009, $2.04 million remained available to draw. Subsequent to the period end, an additional $625,000 was drawn.
• Capital Needs: Management expects to need additional capital to reach sustainable positive cash flow. There is no assurance that existing lenders will continue to provide funds or that new capital will be available on acceptable terms.
• Operational Transition: The Company completed its first in-house production run in May 2009, aiming to reduce long-term cost of goods sold and enhance production flexibility.
• Risks: Key risks include potential termination of the loan facilities, significant revenue reductions due to economic slowdowns (noted in cord blood banking and cell supplier segments), and adverse outcomes from current litigation.

Investor Verification Checklist

• Debt Covenants and Conversion: Verify the terms of the $9 million aggregate loan facility, specifically the 7% interest rate, the January 2010 maturity date, and the conversion rights (85% discount) in the event of a $2 million+ equity financing.
• Related Party Dependence: Assess the risk concentration given that all significant debt and recent financing comes from two related parties (a director and an affiliate).
• Manufacturing Economics: Monitor future quarters to determine if the in-house manufacturing transition successfully lowers the cost of product sales compared to the previous contract manufacturing model.
• Cash Runway: Calculate the remaining runway based on the current cash balance ($86k) and monthly burn rate, considering the remaining $2 million draw capacity.
• Litigation Status: Review the status of the litigation mentioned as a risk factor, as legal fees previously impacted G&A expenses significantly.